Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study.
about
Bisphosphonates: mechanism of action and role in clinical practiceScreening, diagnosis and treatment of osteoporosis: a brief reviewOral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysisBisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies.Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.Bisphosphonates and risk of atrial fibrillation: a meta-analysis.Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis.Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect.Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.Validity of the recorded International Classification of Diseases, 10th edition diagnoses codes of bone metastases and skeletal-related events in breast and prostate cancer patients in the Danish National Registry of Patients.Osteoporosis and gastrointestinal disease.Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis.Mortality following acute medical admission in Denmark: a feasibility study.Osteoporosis therapies: evidence from health-care databases and observational population studies.Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer.Atrial fibrillation and the use of oral bisphosphonates.Intravenous bisphosphonates for postmenopausal osteoporosis.Intravenous bisphosphonate therapy and atrial fibrillation/flutter risk in cancer patients: a nationwide cohort study.Risk of atrial fibrillation among bisphosphonate users: a multicenter, population-based, Italian study.Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials.Influence of Zoledronic Acid on Atrial Electrophysiological Parameters and Electrocardiographic Measurements.Paget's Disease of Bone: A Review of Epidemiology, Pathophysiology and ManagementBisphosphonates for the treatment of osteoporosis: insights for clinicians.Twelve-Minute Daily Yoga Regimen Reverses Osteoporotic Bone Loss.Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case-control studyRelationship of Bisphosphonate Therapy and Atrial Fibrillation/Flutter: Outcomes of Sleep Disorders in Older Men (MrOS Sleep) Study.Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control studyDiagnosis and management of osteoporosis in the older seniorTreatment of osteoporosis with annual iv zoledronic acid: effects on hip fracture.Adverse effects of bisphosphonates: implications for osteoporosis management.Management of osteoporosis in the aging male: focus on zoledronic acid.Prevention of osteoporosis-related fractures among postmenopausal women and older men.Potential mediators of the mortality reduction with zoledronic acid after hip fracture.Atrial fibrillation and bisphosphonate therapy.Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis.Safety of long-term bisphosphonate therapy for the management of osteoporosis.Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies.Adverse drug reactions to osteoporosis treatments.Risks and Benefits of Bisphosphonate Therapies.The effects of zoledronic acid on ECG: a prospective study on patients with bone metastatic cancer.
P2860
Q24644708-15A2D816-9395-48FE-88D3-47EB9F79D8EBQ26996726-FD987280-B6AC-480B-9149-91BD73558A00Q33415484-BA107AB7-AF48-49A6-8DE1-83A6DF6CF592Q33505798-9A2809DE-2CFC-4379-A604-FE6595E5255BQ33715141-345C2496-B8F4-4241-8630-AA9A4441F4FDQ33873740-EABC6A32-58F4-47CC-A595-18EC802C5297Q33886852-2018D28A-D156-4E0F-BE31-6295CE094E0DQ33973902-A5C52A7A-A0CC-4583-B47C-FA012E23B545Q34018048-69D839CF-86CA-452B-AA9B-F2A608C97826Q34143966-58C19DF3-098D-4715-A856-B60E57637A6EQ34178759-1B33E670-F175-4C83-971C-9CB19684B23AQ34189582-A706DBB5-F673-4248-86D4-F97B85FF3EC6Q34240623-0A782941-33A1-4CE2-B0FE-459D10C4705BQ34242906-E8D43799-66B7-423C-9075-44EB191E8E3FQ34488705-F1C5FC8F-B11B-4702-942E-0FB4B8682A17Q34764869-6174A3DF-163F-4A55-9C20-FFBC49646F60Q34863964-A3FD678C-BA47-4CB0-93E8-F5B7BEDC1AC5Q35263110-FD9CC088-1A60-4399-B7E6-76CAE38F44C9Q35597843-8F338E46-CE7A-4040-A4DD-B7DB561FB43AQ35644059-ACEEE1FE-8182-42CF-A416-9A3FA9CB797EQ35732066-68EC40DE-200C-4BAD-8D5F-D603AAD3B615Q36059397-2AA75425-41EA-4C62-B136-BBF30066F6F4Q36443681-EE37DDBB-7454-4B83-9671-0CF1E4A3B7E8Q36852298-24327583-13AD-4E03-8394-D20612981303Q37080899-7F5A8123-D838-4388-B0AC-2CE517C175DCQ37094648-639EFDC1-4FCB-4F8A-BD30-0B22785E8D97Q37131343-849376BE-7340-4556-9173-C6585AC90686Q37199923-BEDB1CF8-6502-43F9-9183-93AB82A4C825Q37230328-5C10CAB8-0664-4786-915E-E012AE398CEBQ37246255-E6FEB754-F99B-4FCA-A68F-F3AE2DDA06F5Q37337113-91ABA797-8B1B-42EA-88BF-58950A0BEB70Q37428448-AE36C38D-5163-45A7-B972-7F3B4D16AA2FQ37542295-0564B3F1-EDEC-4D18-BB02-FA0143008AC7Q37679127-85484257-727F-4700-B427-BF4F408E4653Q37856911-4BE2A857-2C41-4D9B-AB2D-FE6060591E8BQ37866764-492DBF43-8E8F-46E6-BC99-F86EC1B1A61EQ37918967-A96416CD-FC1F-48B5-8502-DEBD0E620CB0Q37973355-CFA843F3-5661-4BE6-84F3-A7F2350E4976Q38533828-E2A87DE9-2D38-4F2E-A114-614C11DC2857Q40984313-77C25958-1F26-4CF9-914B-64FAAD824FC9
P2860
Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Use of bisphosphonates among w ...... tion based case-control study.
@ast
Use of bisphosphonates among w ...... tion based case-control study.
@en
Use of bisphosphonates among w ...... tion based case-control study.
@nl
type
label
Use of bisphosphonates among w ...... tion based case-control study.
@ast
Use of bisphosphonates among w ...... tion based case-control study.
@en
Use of bisphosphonates among w ...... tion based case-control study.
@nl
prefLabel
Use of bisphosphonates among w ...... tion based case-control study.
@ast
Use of bisphosphonates among w ...... tion based case-control study.
@en
Use of bisphosphonates among w ...... tion based case-control study.
@nl
P2093
P2860
P1433
P1476
Use of bisphosphonates among w ...... tion based case-control study.
@en
P2093
John A Baron
Lars Pedersen
Roland D Chapurlat
Steffen Christensen
Steven R Cummings
P2860
P304
P356
10.1136/BMJ.39507.551644.BE
P407
P577
2008-03-11T00:00:00Z